PT - JOURNAL ARTICLE AU - Madrigal-Matute, Julio AU - Bañón Escandell, Sara TI - Colorectal cancer and microbiota modulation for clinical use. A systematic review AID - 10.1101/2021.09.01.21262956 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.01.21262956 4099 - http://medrxiv.org/content/early/2021/09/03/2021.09.01.21262956.short 4100 - http://medrxiv.org/content/early/2021/09/03/2021.09.01.21262956.full AB - Colorectal cancer is one of the top contributors to the global burden of cancer incidence and mortality with genetic and environmental factors contributing to its etiology. Modifiable or environmental factors can be the cause of up to 60% of the risk of developing colorectal cancer. Hence, there is a growing interest in specifically defining what can be improved in our lifestyle to reduce this risk, improve the effectiveness of treatments, reduce side effects, and decrease the risk of recurrence. One of the elements directly related to lifestyle is gut microbiota. The microbial ecosystem has a vital role in colorectal cancer prevention and antitumoral response through modulation of the immune system and production of short-chain fatty acids. Numerous approaches have been used to identify healthy microbiota that can reduce the risk of cancer development, improve treatment efficacy, and reduce side effects.Scientific literature in this subject is growing exponentially and, therefore, systematic reviews and meta-analysis are required to ensure that appropriate recommendations are given to patients.This work aimed to perform a systematic analysis of the published literature to elucidate whether microbiota modulation through pre-, pro-, symbiotic treatment and/or nutritional intervention can be beneficial for patients diagnosed with colorectal cancer.Detailed analysis of published studies shows that some prebiotics, such as inulin and resistant starch, probiotics such as lactic strains producers of short-chain fatty acids, and consumption of unprocessed plant products, can be effective recommendations for patients diagnosed with colorectal cancer. This advice should always be individually tailored and followed up by a healthcare professional with expertise in the field.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for completion of this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a systematic review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere are not restrictions on data availability in this manuscript.CRCcolorectal cancerROSreactive oxygen speciesRNSreactive nitrogen speciesMSIMicrosatellite instabilitySCFAShort chain fatty acidsLPSLipopolysaccharidedMMRdeficient DNA mismatch repairAOMAzoxymethaneDSSDextran sodium sulfateTNF-αtumor necrosis factor alphaMPOMyeloperoxidasePCNAProliferation cellular nuclear antigenSLC5A8Solute Carrier Family 5 Member 8GPR43G protein-coupled receptor 43CEACarcinoembryonic antigenAPCAdenomatous polyposis coliDHM1,2-dimethyl hydrazineTGF-βTransforming growth factor betaTLR2toll-like receptor 2DCdendritic cellsPD-1Programmed cell death protein 1PDL-1Programmed cell death protein ligand 1CTLA-4Cytotoxic T-Lymphocyte Associated Protein 4CYPCytochrome P450 FamilyGSTM1Glutathione S-Transferase Mu 1SULT1Sulfotransferase Family-1PYYPeptide tyrosinePPARγperoxisome proliferator activated receptor gamma6,BR6-bromoisatinNEmarine extractMDMediterranean dietLFDlow fat dietHFDhigh fat dietEPAEicosapentanoic acidPUFApolyunsaturated fatty acidsCRPC reactive proteinSFRP2Secreted Frizzled Related Protein 2DNMT1DNA Methyltransferase 1COX-2Cyclooxygenase-2PGE2Prostaglandin E2CxclC-X-C Motif Chemokine LigandBikBCL2 Interacting KillerKCKeratinocytes-derived chemokineGr-1Glucocorticoid Receptor-1CTNNB1Beta catenin 1EGFREpidermal growth factor receptorTYMSThymidylate SynthetaseLPELisophosphatidiletanolamineLPCLisophosphatidylcholineG-CSFGranulocyte Colony-Stimulating FactorGM-CSFGranulocyte Macrophage Colony-Stimulating FactorHDACHistone DeacetylaseJAM1F11 Receptor5-FU5-florouracilEGCGepigallocatechin-3-gallate